Literature DB >> 9789707

Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease.

G Friedberg1, J Zoldan, A Weizman, E Melamed.   

Abstract

The Parkinson Psychosis Rating Scale (PPRS) was designed to assess the severity of specific symptoms of levodopa-induced psychosis in patients with Parkinson's disease. The scale is administered by the clinician and consists of six items, each rated from 1 (no symptoms) to 4 (extreme symptoms); total score ranges from 6-24 points. To test its reliability, validity, and stability, the authors administered the PPRS to 29 patients with parkinsonian psychosis before and after a 6-week course of treatment with the 5HT3 antagonist ondansetron. Each patient and their caregivers were interviewed by three raters. Results were compared with two other available psychotic symptom scales and one cognitive scale given to the same patients. It was found that the interrater reliability for the total PPRS scores and for each of the individual items was high (Spearman's rho = 0.80-0.99). A significant reduction in PPRS scores was obtained after ondansetron administration, concomitant with a decrease in the Global Functional Impairment score, which was assessed by the family. The changes in PPRS scores occurred irrespective of cognitive dysfunction, as measured by the Minimental State Examination. It appears that the PPRS is a relevant, reliable, valid, and easily-administered instrument for measuring the severity of parkinsonian psychosis. Further studies are needed to evaluate its utility in other organic psychoses and in the assessment of additional pharmacologic treatments for levodopa-induced psychosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9789707

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  29 in total

1.  Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.

Authors:  P Pollak; F Tison; O Rascol; A Destée; J J Péré; J M Senard; F Durif; I Bourdeix
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

2.  Quetiapine in the treatment of psychosis in Parkinson's disease.

Authors:  Paul Shotbolt; Mike Samuel; Anthony David
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

3.  Scales in Parkinson's disease.

Authors:  Georg Ebersbach; Horst Baas; Ilona Csoti; Martina Müngersdorf; Günther Deuschl
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

4.  Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease.

Authors:  Daniel Weintraub; Knashawn H Morales; John E Duda; Paul J Moberg; Matthew B Stern
Journal:  Parkinsonism Relat Disord       Date:  2006-06-22       Impact factor: 4.891

5.  Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores.

Authors:  Eugenia Mamikonyan; Paul J Moberg; Andrew Siderowf; John E Duda; Tom Ten Have; Howard I Hurtig; Matthew B Stern; Daniel Weintraub
Journal:  Parkinsonism Relat Disord       Date:  2008-07-02       Impact factor: 4.891

6.  Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease.

Authors:  James F Morley; Daniel Weintraub; Eugenia Mamikonyan; Paul J Moberg; Andrew D Siderowf; John E Duda
Journal:  Mov Disord       Date:  2011-05-24       Impact factor: 10.338

7.  Psychometric Properties and Characteristics of the North-East Visual Hallucinations Interview in Parkinson's Disease.

Authors:  Kelsey A Holiday; Eva Pirogovsky-Turk; Vanessa L Malcarne; J Vincent Filoteo; Irene Litvan; Stephanie L Lessig; David Song; Dawn M Schiehser
Journal:  Mov Disord Clin Pract       Date:  2017-03-16

8.  Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.

Authors:  Herbert Y Meltzer; Roger Mills; Stephen Revell; Hilde Williams; Ann Johnson; Daun Bahr; Joseph H Friedman
Journal:  Neuropsychopharmacology       Date:  2009-11-11       Impact factor: 7.853

Review 9.  Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.

Authors:  Shyam C Panchal; William G Ondo
Journal:  Curr Psychiatry Rep       Date:  2018-01-27       Impact factor: 5.285

Review 10.  Instruments for holistic assessment of Parkinson's disease.

Authors:  Pablo Martinez-Martin
Journal:  J Neural Transm (Vienna)       Date:  2013-03-10       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.